Quantcast

Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System

July 13, 2009

MINNEAPOLIS, July 13 /PRNewswire-FirstCall/ — Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,536,226 entitled, “Electro-Nerve Stimulator System and Methods.” The patent covers the company’s Urgent(R) PC system and stimulation methods for treatment of the overactive bladder (“OAB”) symptoms of urinary urgency, urge incontinence and frequency of urinary voids.

The Urgent PC Neuromodulation System is a minimally invasive, office-based, nonsurgical system designed to deliver retrograde access to the sacral plexus through percutaneous electrical stimulation of the posterior tibial nerve. The Urgent PC system combines a pulse generator and a lead set to transfer electrical current from the pulse generator to the posterior tibial nerve, and includes a single use feature to prevent reuse of the lead set. By preventing reuse of lead sets, the Urgent PC System eliminates the health risks otherwise associated with re-using the same electrodes.

“We are very pleased that the United States Patent Office has awarded this patent on the unique features of our stimulation systems and methods,” said David Kaysen, President and CEO. “This newly issued patent underscores our commitment to protect the unique features of the Urgent PC system. The system’s ease of use and treatment effectiveness, coupled with a minimally invasive procedure and single-use features, are seen as key positives by our many clinical users as well as patients treated for the symptoms of OAB.”

About the Urgent PC Neuromodulation System

The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these symptoms.

Uroplasty sells the Urgent PC system in the United States, Canada, and countries recognizing the CE mark. Outside of the United States, Urgent PC is also indicated for the treatment of fecal incontinence.

For more information about the Urgent PC Neuromodulation System, please call 866-277-0466 or visit www.uroplasty.com.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence – symptoms often associated with overactive bladder.

We also offer Macroplastique(R) Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. Forward-looking statements include statements about the scope of coverage and potential applications for Uroplasty’s patents, whether Uroplasty’s issued patents will be challenged and whether such challenges will have an adverse effect on the scope of the patents; whether Uroplasty will pursue enforcement of its issued patents or be successful in any such enforcement efforts; whether Uroplasty will successfully prosecute additional patent applications and if so, whether such applications will lead to the issuance of additional patents. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.


    For Further Information:

    Uroplasty, Inc.                               EVC Group
    ---------------                               ---------
    David Kaysen, President and CEO, or           Doug Sherk (Investors)
    Medi Jiwani, Vice President, CFO, and         415.896.6820
     Treasurer,
    952.426.6140                                  Chris Gale (Media)
                                                  646.201.5431

SOURCE Uroplasty, Inc.


Source: newswire



comments powered by Disqus